Assess metabolic syndrome risk using ATP III and IDF criteria. Enter waist, blood pressure, glucose, triglycerides, and HDL to check all 5 diagnostic criteria.
Metabolic syndrome is a cluster of five interconnected cardiometabolic risk factors that dramatically increases the risk of cardiovascular disease (CVD), type 2 diabetes, stroke, and all-cause mortality. Approximately 35% of U.S. adults — over 85 million people — meet the diagnostic criteria, yet many are unaware. Identifying metabolic syndrome early allows targeted lifestyle interventions that can reverse it entirely in many cases.
This calculator evaluates your five core biomarkers against both the NCEP ATP III and International Diabetes Federation (IDF) diagnostic criteria: waist circumference (central obesity), triglycerides, HDL cholesterol, blood pressure, and fasting glucose. ATP III requires any 3 of 5 criteria; IDF requires central obesity plus any 2 additional criteria. The tool accounts for medication use (antihypertensives, statins, glucose-lowering drugs), which counts as meeting the respective criteria regardless of current lab values.
Beyond simple diagnosis, the calculator provides a risk score visualization, TG:HDL ratio (a proxy for insulin resistance and small dense LDL), a side-by-side comparison of ATP III vs. IDF thresholds, and an evidence-based intervention table showing the expected impact of lifestyle changes. The 5–10% weight loss recommendation from the Diabetes Prevention Program (DPP) trial is particularly compelling — it reduced diabetes incidence by 58%.
Metabolic syndrome is often silent — each individual marker may seem "borderline" yet the combination poses significant risk. This calculator systematically checks all five criteria against two international standards, highlights your TG:HDL ratio as an insulin resistance proxy, and provides evidence-based interventions to guide action. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain.
ATP III Diagnosis: ≥3 of 5 criteria met. IDF Diagnosis: Central obesity (waist ≥94 cm men / ≥80 cm women) PLUS ≥2 of: TG ≥150, HDL <40 M/<50 F, BP ≥130/85, FG ≥100. TG:HDL Ratio = Triglycerides / HDL Cholesterol (insulin resistance proxy; >3.5 suggests risk).
Result: 5/5 criteria met — Metabolic Syndrome (ATP III & IDF positive)
This 42-inch waist male meets all five ATP III criteria: waist ≥40 in, TG ≥150, HDL <40, BP ≥130/85, FG ≥100. TG:HDL ratio of 4.3 suggests significant insulin resistance. Lifestyle intervention (5–10% weight loss, 150 min/wk exercise) is first-line treatment.
The common thread linking all five metabolic syndrome criteria is insulin resistance. When cells resist insulin's signal to absorb glucose, the pancreas compensates by producing more insulin (hyperinsulinemia). This excess insulin promotes: (1) central fat accumulation, (2) hepatic triglyceride overproduction, (3) reduced HDL production, (4) sodium retention and sympathetic nervous system activation (raising blood pressure), and (5) eventually beta-cell exhaustion and hyperglycemia. Treating insulin resistance — through exercise, weight loss, and dietary changes — addresses the root cause rather than individual symptoms.
Metabolic syndrome thresholds were developed primarily in European populations. Asian populations develop insulin resistance and visceral adiposity at lower waist circumferences — the IDF recommends ≥90 cm for Asian men (vs. 94 cm European). South Asian, Hispanic, and African American populations have higher metabolic syndrome prevalence at equivalent BMI levels, highlighting the importance of waist circumference over BMI as a screening tool.
Emerging evidence links metabolic syndrome to increased risk of colorectal, breast (postmenopausal), endometrial, liver, and pancreatic cancers. The mechanisms involve chronic hyperinsulinemia (insulin is a growth factor), chronic inflammation (elevated CRP, TNF-α, IL-6), and altered adipokine signaling. Cancer prevention is an additional reason to address metabolic syndrome aggressively.
Metabolic syndrome (formerly Syndrome X) is a cluster of five risk factors — central obesity, high triglycerides, low HDL, high blood pressure, and high fasting glucose — that occur together and dramatically increase the risk of heart disease, stroke, and type 2 diabetes. Use this as a practical reminder before finalizing the result.
ATP III (American) requires any 3 of 5 criteria regardless of order. IDF (International) requires central obesity as mandatory, plus any 2 of the other 4. IDF uses tighter waist cutoffs (94 cm men, 80 cm women vs. 102/88 cm). IDF diagnoses more people globally.
Yes. The PREDIMED trial showed a Mediterranean diet resolved metabolic syndrome in 37% of participants at 2 years. The DPP trial showed 5–10% weight loss reduced diabetes risk by 58%. Exercise (150 min/wk) independently improves all five markers. Reversal is entirely possible with sustained lifestyle changes.
The triglyceride-to-HDL ratio is a simple, inexpensive proxy for insulin resistance and small dense LDL particles. A ratio >3.5 suggests insulin resistance; >5.0 indicates high cardiovascular risk. It is often a better predictor of heart disease than LDL cholesterol alone.
Yes, even meeting 1–2 criteria increases cardiometabolic risk above baseline. Metabolic syndrome exists on a continuum, not a binary threshold. Addressing borderline values now prevents progression. Think of it as an early warning system.
Yes. Pediatric metabolic syndrome affects ~10% of U.S. adolescents and up to 30% of obese children. Modified criteria with age-appropriate cutoffs are used. Childhood metabolic syndrome strongly predicts adult cardiovascular disease and type 2 diabetes.